True or false: Assessing biological interactions in biomaterials is only necessary during initial testing.

The statement is false because assessing biological interactions in biomaterials is an ongoing process that extends beyond just initial testing. Once a biomaterial is introduced into biomedical applications—whether in implants, drug delivery systems, or tissue engineering—its interactions with biological systems can change over time due to factors like degradation, response to the immune system, and varying environmental conditions. Continuous assessment helps ensure safety, effectiveness, and compatibility throughout the lifecycle of the biomaterial. This includes examining biocompatibility, potential toxicity, and how well the material integrates with surrounding tissues over time. The dynamic nature of biological environments means that understanding these interactions is crucial at multiple stages, including initial development, clinical application, and post-market evaluation.